Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla faces quiet end following stock collapse

This article was originally published in Scrip

Executive Summary

La Jolla Pharmaceuticals will consider ending operations after the trial suspension of its only clinical candidate left its share price in tatters. The firm's share price tumbled by 92% to $0.20 earlier this month after a study of its lupus candidate Riquent (abetimus sodium) failed to show a benefit and was subsequently halted.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC000371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel